Vaxcyte, Inc. Share Price

PCVX

US92243G1085

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 07:05:22 24/06/2025 pm IST			5-day change	1st Jan Change
33.70 ^USD	+1.35%		-3.15%	-59.38%

11/06	Vaxcyte, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01:20 PM
13/05	Vaxcyte, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08:40 AM

Last Transcript: Vaxcyte, Inc.

Vaxcyte, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01:20 PM

11/06

More transcripts

Analysts' recommendations: Vaxcyte, Inc.

Analyst recommendations: AMD, Walt Disney, Applovin, Ionq, Uber...	08/05
Analyst recommendations: Autozone, Block, Ulta Beauty, Lululemon…	01/04
Needham Cuts Price Target on Vaxcyte to $90 From $140, Maintains Buy Rating	31/03	MT
Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...	10/24/10
Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	10/24/10	MT

More recommendations

News in other languages: Vaxcyte, Inc.

En bourse, la pharma se méfie du nouvel homme fort de la FDA	07/05
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Apple, Oracle, Progressive, Dollar Tree...	10/24/10
Bourse Zurich: les indices en ordre dispersé pour entamer la semaine	16/23/16
Aktien Schweiz von gestiegener Riskoneigung belastet	16/23/16
Lonza: contratto per produzione vaccini a Visp, fino a 300 impieghi	16/23/16

More news

Managers and Directors: Vaxcyte, Inc.

Manager	Title	Age	Since
Jeff Fairman PRN	Corporate Officer/Principal	61	27/05/2013
Grant Pickering CEO	Chief Executive Officer	57	01/11/2013
Andrew Guggenhime DFI	Director of Finance/CFO	55	01/05/2020

Director	Title	Age	Since
Grant Pickering BRD	Director/Board Member	57	01/11/2013
Heath Lukatch BRD	Director/Board Member	57	01/05/2018
Halley Gilbert BRD	Director/Board Member	55	01/04/2020

More insiders

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Employees

414

Sector

Biotechnology & Medical Research

Calendar

12/08 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24/25/24	33.25 $	+1.16%	11,23,750
20/25/20	32.87 $	-1.59%	25,20,873
18/25/18	33.40 $	-0.71%	8,92,461
17/25/17	33.64 $	-2.01%	8,99,044

Delayed Quote Nasdaq, June 24, 2025 at 01:30 am IST

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Capitalization	428.94Cr 371.63Cr 348.56Cr 317.71Cr 588.96Cr 37TCr 666.31Cr 4.13TCr 1.59TCr 17TCr 1.61TCr 1.58TCr 63TCr	P/E ratio 2025 *	-6.9x	P/E ratio 2026 *	-6.4x
Enterprise value	428.94Cr 371.63Cr 348.56Cr 317.71Cr 588.96Cr 37TCr 666.31Cr 4.13TCr 1.59TCr 17TCr 1.61TCr 1.58TCr 63TCr	EV / Sales 2025 *	-	EV / Sales 2026 *	172x
Free-Float	97.87%	Yield 2025 *	-	Yield 2026 *	-

Vaxcyte : May Investor Presentation (104259)	08/05	PU
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update	08/05	GL
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors	01/05	GL
Vaxcyte : March Investor Presentation (008fbb)	02/04	PU
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study	31/03	GL

1 day	+1.38%
1 week	-3.15%
Current month	+2.34%
1 month	+2.18%
3 months	-55.46%
6 months	-61.82%
Current year	-59.38%

1 week	32.43	33.71
1 month	31.07	38.39
Current year	27.66	93.77
1 year	27.66	121.06
3 years	19.43	121.06
5 years	15.51	121.06
10 years	15.51	121.06

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VAXCYTE, INC.	+1.35%	-3.15%	-55.63%	+59.09%	428.94Cr
REGENERON PHARMACEUTICALS, INC.	+0.86%	-2.06%	-51.39%	-15.72%	5.41TCr
ARGENX SE	+2.04%	+0.42%	+17.09%	+41.18%	3.28TCr
WUXI APPTEC CO., LTD.	0.00%	-4.66%	+61.20%	-30.90%	2.61TCr
BIONTECH SE	+1.36%	-3.12%	+21.70%	-22.13%	2.54TCr
INSMED INCORPORATED	-1.15%	+3.77%	+55.05%	+431.08%	2TCr
SUMMIT THERAPEUTICS INC.	+0.61%	+2.21%	+157.12%	+1,704.42%	1.51TCr
GENMAB A/S	-1.37%	-7.15%	-25.87%	-40.05%	1.29TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.67%	-1.17%	+114.53%	-67.10%	1.27TCr
EXELIXIS, INC.	+2.69%	+3.88%	+95.36%	+103.33%	1.18TCr
Average	+1.02%	-2.65%	+38.92%	+216.32%	2.15TCr
Weighted average by Cap.	+0.92%	-2.31%	+25.17%	+156.48%

Vaxcyte, Inc. Share Price

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Valuation: Vaxcyte, Inc.

Chart: Vaxcyte, Inc.

Latest news: Vaxcyte, Inc.

Last Transcript: Vaxcyte, Inc.

Analysts' recommendations: Vaxcyte, Inc.

Press Releases: Vaxcyte, Inc.

News in other languages: Vaxcyte, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Vaxcyte, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

	2025 *	2026 *
Net sales	-	2.5Cr 2.17Cr 2.03Cr 1.85Cr 3.43Cr 216.48Cr 3.88Cr 24Cr 9.26Cr 99Cr 9.38Cr 9.18Cr 365.94Cr
Net income	-66Cr -57Cr -53Cr -49Cr -90Cr -5.7TCr -102.24Cr -633.98Cr -243.82Cr -2.61TCr -246.97Cr -241.71Cr -9.63TCr	-74Cr -64Cr -60Cr -55Cr -101.36Cr -6.39TCr -114.68Cr -711.08Cr -273.47Cr -2.93TCr -277.01Cr -271.11Cr -11TCr
Net Debt	-	-